| 1 |
33125153 | Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer. | 2020 Dec |
1 |
| 2 |
29526950 | Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib. | 2018 Aug 15 |
2 |
| 3 |
27070423 | In Vitro Drug Sensitivity Tests to Predict Molecular Target Drug Responses in Surgically Resected Lung Cancer. | 2016 |
1 |
| 4 |
27126828 | Specialty pharmacy services for patients receiving oral medications for solid tumors. | 2016 Jun 1 |
1 |
| 5 |
25788996 | Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report. | 2015 Apr |
2 |
| 6 |
25990337 | [Treatment of lung cancer guided by genomic tumour profiles]. | 2015 |
2 |
| 7 |
26788139 | EML4-ALK translocation is associated with early onset of disease and other clinicopathological features in Chinese female never-smokers with non-small-cell lung cancer. | 2015 Dec |
1 |
| 8 |
24355409 | Targeting the MET gene for the treatment of non-small-cell lung cancer. | 2014 Feb |
2 |
| 9 |
24566025 | [Therapeutic impact of molecular diagnosis in metastatic non-small cell lung cancer: targeted therapies in 2013]. | 2014 Feb-Apr |
1 |
| 10 |
25407901 | Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset. | 2014 Nov 18 |
1 |
| 11 |
23714542 | Lung cancer in 2013: state of the art therapy for metastatic disease. | 2013 |
1 |
| 12 |
23733083 | Non-small cell lung cancer--genetic predictors. | 2013 Jun |
1 |
| 13 |
24192124 | EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. | 2013 Nov |
1 |
| 14 |
22286583 | Personalized therapy of lung cancer. | 2012 |
3 |
| 15 |
23154552 | Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. | 2012 Dec |
1 |
| 16 |
21168933 | EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. | 2011 Feb |
2 |
| 17 |
22005476 | Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. | 2011 Nov |
1 |